Protagonist Therapeutics officer proposes $339K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Protagonist Therapeutics, Inc. (PTGX) is the issuer named in officer Arturo Molina’s Form 144 notice of a proposed sale of 2,718 common shares, with an aggregate market value of $338,798.70. The notice lists November 16, 2026, as the approximate sale date and says the shares were acquired that day from the issuer through restricted stock vesting under a registered plan, for services rendered.
Key Figures
Key Terms
Restricted stock vesting financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.